BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11907916)

  • 1. A cohort study of hormone replacement therapy given to women previously treated for breast cancer.
    Dew J; Eden J; Beller E; Magarey C; Schwartz P; Crea P; Wren B
    Climacteric; 1998 Jun; 1(2):137-42. PubMed ID: 11907916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer in premenopausal women: recurrence and survival rates and relationship to hormone replacement therapy.
    Durna EM; Heller GZ; Leader LR; Sjoblom P; Eden JA; Wren BG
    Climacteric; 2004 Sep; 7(3):284-91. PubMed ID: 15669553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
    Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
    JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2003 Mar; 6(1):45-52. PubMed ID: 12725664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Menopausal hormone therapy (HT) in patients with breast cancer.
    Batur P; Blixen CE; Moore HC; Thacker HL; Xu M
    Maturitas; 2006 Jan; 53(2):123-32. PubMed ID: 16368466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone replacement therapy in women with a history of breast cancer.
    Ylikorkala O; Metsä-Heikkilä M
    Gynecol Endocrinol; 2002 Dec; 16(6):469-78. PubMed ID: 12626034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
    Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
    JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA; Blake JM; Crosignani PG
    Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestins and recurrence in breast cancer survivors.
    Chlebowski RT; Anderson GL
    J Natl Cancer Inst; 2005 Apr; 97(7):471-2. PubMed ID: 15812065
    [No Abstract]   [Full Text] [Related]  

  • 13. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
    Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
    J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
    Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
    N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Ross RK; Paganini-Hill A; Wan PC; Pike MC
    J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.
    von Schoultz E; Rutqvist LE;
    J Natl Cancer Inst; 2005 Apr; 97(7):533-5. PubMed ID: 15812079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
    J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
    Osborne CR; Duncan A; Sedlacek S; Paul D; Holmes F; Vukelja S; Kasper M; Wilks S; Schneider A; McGee R; Meyer WG; O'Shaughnessy JA
    Breast Cancer Res Treat; 2009 Aug; 116(3):521-7. PubMed ID: 19139988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing menopause after breast cancer: balancing risks and benefits.
    Moore HC
    Cleve Clin J Med; 2001 Mar; 68(3):243-8. PubMed ID: 11263852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.